Temporal trends in treatment outcomes for HIV-1 and HIV-2-infected adults enrolled in Côte d'Ivoire's national antiretroviral therapy program

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Auld, Andrew F ^a   Ekra, Kunomboa A ^b   Shiraishi, Ray W ^a   Tuho, Moise Z ^c   Kouakou, Joseph S ^d   Mohamed, Fayama ^d,e   Ettieg̀ne Traoré, Virginie ^c   Sabatier, Jennifer ^a   Essombo, Joseph ^d   Adjorlolo Johnson, Georgette ^d   Marlink, Richard ^d   Ellerbrock, Tedd V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Ministry of Health   (Côte d’Ivoire)

^d ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^e Directorate General of Budget and Finance   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DEATH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PROGRAM EVALUATION; SURVIVAL RATE; TRENDS; VIROLOGY;

ADULT; ANTI-HIV AGENTS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MORTALITY; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84901455144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098183     Document Type: Article

References (78)

1. Tienen C, van der Loeff MS, Zaman SM, Vincent T, Sarge-Njie R, et al. (2010) Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J Acquir Immune Defic Syndr 53: 640-647.
2. van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, et al. (2006) Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 35: 1322-1328. (Pubitemid 44605560)
3. Djomand G, Greenberg AE, Sassan-Morokro M, Tossou O, Diallo MO, et al. (1995) The epidemic of HIV/AIDS in Abidjan, Cote d'Ivoire: a review of data collected by Projet RETRO-CI from 1987 to 1993. J Acquir Immune Defic Syndr Hum Retrovirol 10: 358-365.
4. Joint United Nations Programme on HIV/AIDS (2012) Report on the Global AIDS Epidemic. Available: http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS- Global-Report-2012-with-annexes-en.pdf. Accessed 1 April 2013.
5. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2- year outcomes and determinants. AIDS 22: 873-882. (Pubitemid 351563837)
6. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, et al. (1993) Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 270: 2083-2086. (Pubitemid 23318173)
7. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI (2011) Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low- Resource Settings. AIDS Res Treat 2011: 463704.
8. Harries K, Zachariah R, Manzi M, Firmenich P, Mathela R, et al. (2010) Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. Trans R Soc Trop Med Hyg 104: 154-161.
9. United Nations Development Programme (2011) The Conflict in Côte d'Ivoire and its Effect on West African Countries: A Perspective from the Ground. Available: http://www.crin.org/docs/Cote-d-Ivoire-vulnerable-groups.pdf. Accessed 29 March 2013.
10. Joint United Nations Programme on HIV/AIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. Available: http://www. unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/ gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 17 February 2014.
11. Messou E, Kouakou M, Gabillard D, Gouesse P, Kone M, et al. (2011) Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Cote d'Ivoire. J Acquir Immune Defic Syndr 57 Suppl 1: S34-39.
12. Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, et al. (2009) Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 52: 49- 55.
13. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Four- Year Treatment Outcomes of Adult Patients Enrolled in Mozambique's Rapidly Expanding Antiretroviral Therapy Program. PLoS One 6: e18453.
14. Government Accountability Office (2012) Designing evaluations - 2012 revision. Available: http://www.gao.gov/products/GAO-12-208G. Accessed 17 January 2013.
15. Institute of Medicine (2013) Evaluation of PEPFAR. Available: http://www. who.int/hiv/pub/progress-report2011/en/. Accessed 1 April 2013.
16. Montaner JS, Lima VD, Williams BG (2010) Evaluating outcomes of the President's Emergency Plan for AIDS Relief in Africa. Ann Intern Med 152: 131-132; author reply 132-133.
17. Boerma JT, Stanecki KA, Newell ML, Luo C, Beusenberg M, et al. (2006) Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ 84: 145-150. (Pubitemid 43275773)
18. Bennett S, Boerma JT, Brugha R (2006) Scaling up HIV/AIDS evaluation. Lancet 367: 79-82. (Pubitemid 43038673)
19. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
20. Stringer J, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793. (Pubitemid 44223102)
21. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257-265.
22. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
23. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach - 2010 revision. Available: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed 17 January 2013.
24. Fairley CK, Permana A, Read TR (2005) Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med 6: 366-369. (Pubitemid 41335147)
25. Lucas GM, Chaisson RE, Moore RD (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: 81-87. (Pubitemid 29340558)
26. Grossberg R, Zhang Y, Gross R (2004) A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 57: 1107-1110. (Pubitemid 39451804)
27. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons. 231 p.
28. Royston P (2004) Multiple imputation of missing values. The Stata Journal 4(3): 227-241.
29. Royston P (2005) Multiple imputation of missing values: update. The Stata Journal 5(2): 188-201.
30. Royston P (2005) Multiple imputation of missing values: update of ice. The Stata Journal 5(4): 527-536.
31. White IR, Royston P (2009) Imputing missing covariate values for the Cox model. Stat Med 28: 1982-1998.
32. Royston P, Carlin JB, White IR (2009) Multiple imputation of missing values: new features for mim. The Stata Journal 9(2): 252-264.
33. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, et al. (2012) Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 59: e9-16.
34. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26: 2389-2430. (Pubitemid 46730255)
35. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
36. Fox MP, Rosen S (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15 Suppl 1: 1-15.
37. Béchu N (2006) The impact of AIDS on the economy of families in Côte d'Ivoire: Changes in consumption among AIDS-affected households. Available: http://www.ceped.org/cdrom/orphelins-sida-2006/pdf/confront-aids- chapter-16.pdf. Accessed 7 January 2013.
38. World Food Programme (2011) World Food Programme - fighting hunger worldwide - Cote d'Ivoire. Available: http://www.wfp.org/countries/ c%C3%B4te-d-ivoire/overview. Accessed 7 January 2013.
39. Tirivayi N, Koethe JR, Groot W (2012) Clinic-Based Food Assistance is Associated with Increased Medication Adherence among HIV-Infected Adults on Long-Term Antiretroviral Therapy in Zambia. J AIDS Clin Res 3: 171.
40. Tiyou A, Belachew T, Alemseged F, Biadgilign S (2012) Food insecurity and associated factors among HIV-infected individuals receiving highly active antiretroviral therapy in Jimma zone Southwest Ethiopia. Nutr J 11: 51.
41. Weiser SD, Gupta R, Tsai AC, Frongillo EA, Grede N, et al. (2012) Changes in food insecurity, nutritional status, and physical health status after antiretroviral therapy initiation in rural Uganda. J Acquir Immune Defic Syndr 61: 179-186.
42. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, et al. (2011) Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr 56: 356-364.
43. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, et al. (2009) HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 103: 601-606.
44. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84. (Pubitemid 44306492)
45. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, et al. (2011) Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 56: e1-8.
46. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
47. Forster M, Bailey C, Brinkhof MW, Graber C, Boulle A, et al. (2008) Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ 86: 939-947.
48. Musheke M, Bond V, Merten S (2013) Deterrents to HIV-Patient Initiation of Antiretroviral Therapy in Urban Lusaka, Zambia: A Qualitative Study. AIDS Patient Care STDS.
49. Musheke M, Bond V, Merten S (2012) Individual and contextual factors influencing patient attrition from antiretroviral therapy care in an urban community of Lusaka, Zambia. J Int AIDS Soc 15 Suppl 1: 1-9.
50. Duff P, Kipp W, Wild TC, Rubaale T, Okech-Ojony J (2010) Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc 13: 37.
51. Dang BN, Westbrook RA, Rodriguez-Barradas MC, Giordano TP (2012) Identifying drivers of overall satisfaction in patients receiving HIV primary care: a cross-sectional study. PLoS One 7: e42980.
52. Tran BX, Nguyen NP (2012) Patient satisfaction with HIV/AIDS care and treatment in the decentralization of services delivery in Vietnam. PLoS One 7: e46680.
53. Roberts KJ (2002) Physician-patient relationships, patient satisfaction, and antiretroviral medication Adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS 16: 43-50.
54. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB (2004) Better physicianpatient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 19: 1096-1103. (Pubitemid 39552579)
55. Vahey DC, Aiken LH, Sloane DM, Clarke SP, Vargas D (2004) Nurse burnout and patient satisfaction. Med Care 42: II57-66.
56. Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, et al. (2012) Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 380: 889-898.
57. Harries AD, Zachariah R, Lawn SD, Rosen S (2010) Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15 Suppl 1: 70-75.
58. Decroo T, Telfer B, Biot M, Maikere J, Dezembro S, et al. (2011) Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr 56: e39-44.
59. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, et al. (2012) Retention and risk factors for attrition among adults in antiretroviral treatment programs in Tanzania, Uganda and Zambia [Abstract MOAC0305]. XIX International AIDS Conference Washington D.C. July 22-27. Available: https://docs.google.com/viewer?a=v&q=cache:TWoCw06pt6IJ:pag.aids2012. org/PAGMaterial/aids2012/PPT/1411-2859/aids%2520july%25202012%2520 koole%2520final. pptx +IAC+ 2012 +olivier+ koole+ retention&hl = en&gl = us& pid = bl&srcid = ADGEESjSgUWPgjofBhkLNPnpYEmtTZHSSfGm1wZFltG9MahEWHUm8P1zgSZ4JhpPY3WMdlqQ7K64-N- SfdbGkk9jwgaz- 0tD3zfFV5j9ruUO879xRGJfwydp-xWrkLazZqDiTQ5a9Jmh&sig =AHIEtbR U0FW-mWBE0uES8B5PZ8hdg9OYXg. Accessed 27 March 2013.
60. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, et al. (2007) Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 46: 56-61. (Pubitemid 47507434)
61. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily cotrimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278-1286.
62. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R (2009) The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 14: 722-731.
63. United Nations (2008) World Population Prospects: the 2008 revision. Available: http://www.un.org/esa/population/publications/wpp2008/wpp2008- highlights.pdf. Accessed 1 February 2014.
64. Rajaratnam JK, Marcus JR, Levin-Rector A, Chalupka AN, Wang H, et al. (2010) Worldwide mortality in men and women aged 15-59 years from 1970 to 2010: a systematic analysis. Lancet 375: 1704-1720.
65. Owens IPF (2002) Sex Differences in Mortality Rate. Science 297: 2008.
66. Zuk M, McKean KA (1996) Sex differences in parasite infections: Patterns and processes. International Journal for Parasitology 26: 1009-1024. (Pubitemid 26419313)
67. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 3: e1725.
68. Shimeles A (2010) Migration Patterns, Trends and Policy Issues in Africa. Available: http://www.afdb.org/fileadmin/uploads/afdb/Documents/Project- related- Procurement/WORKING%20119%20word%20document%20AA.pdf. Accessed 1 October 2013.
69. Zanoni BC, Mayer KH (2014) The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities. AIDS Patient Care STDS 28: 128-135.
70. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, et al. (1999) Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13: 1477-1483. (Pubitemid 29396678)
71. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, et al. (2004) Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9: 57-65. (Pubitemid 38313948)
72. Isaka Y, Miki S, Kawauchi S, Suyama A, Sugimoto H, et al. (2001) A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch Virol 146: 743-755. (Pubitemid 32437309)
73. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, et al. (2003) Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17 Suppl 3: S49-54. (Pubitemid 36951669)
74. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, et al. (2009) Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis 48: 476-483.
75. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, et al. (2003) Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 17 Suppl 3: S55-61. (Pubitemid 36951670)
76. Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, et al. (2008) Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 8: 21.
77. Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, et al. (2005) Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol 75: 381-390. (Pubitemid 40175902)
78. Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, et al. (2010) Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS One 5: e13414.